Guilin Sanjin Pharmaceutical Co Ltd (002275) - Total Liabilities
Based on the latest financial reports, Guilin Sanjin Pharmaceutical Co Ltd (002275) has total liabilities worth CN¥1.05 Billion CNY (≈ $154.36 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 002275 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Guilin Sanjin Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Guilin Sanjin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guilin Sanjin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hapvida Participações e Investimentos S.A.
SA:HAPV3
|
Brazil | R$24.04 Billion |
|
Trican Well Service Ltd.
TO:TCW
|
Canada | CA$317.87 Million |
|
Orezone Gold Corporation
AU:ORE
|
Australia | AU$266.84 Million |
|
Shanghai Aladdin Biochemical Technology Co. Ltd. A
SHG:688179
|
China | CN¥1.42 Billion |
|
Shunfa Hengye Corp
SHE:000631
|
China | CN¥1.72 Billion |
|
Topscore Fashion
SHG:603608
|
China | CN¥357.21 Million |
|
Rackspace Technology Inc
NASDAQ:RXT
|
USA | $3.98 Billion |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
China | CN¥1.29 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Guilin Sanjin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002275 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guilin Sanjin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total liabilities of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.22 Billion ≈ $178.88 Million |
+9.24% |
| 2023-12-31 | CN¥1.12 Billion ≈ $163.76 Million |
-2.82% |
| 2022-12-31 | CN¥1.15 Billion ≈ $168.51 Million |
-8.32% |
| 2021-12-31 | CN¥1.26 Billion ≈ $183.80 Million |
+36.04% |
| 2020-12-31 | CN¥923.27 Million ≈ $135.10 Million |
+53.83% |
| 2019-12-31 | CN¥600.18 Million ≈ $87.83 Million |
+0.12% |
| 2018-12-31 | CN¥599.47 Million ≈ $87.72 Million |
+4.14% |
| 2017-12-31 | CN¥575.65 Million ≈ $84.24 Million |
+29.58% |
| 2016-12-31 | CN¥444.26 Million ≈ $65.01 Million |
+6.64% |
| 2015-12-31 | CN¥416.59 Million ≈ $60.96 Million |
-10.04% |
| 2014-12-31 | CN¥463.07 Million ≈ $67.76 Million |
-4.74% |
| 2013-12-31 | CN¥486.11 Million ≈ $71.13 Million |
+19.36% |
| 2012-12-31 | CN¥407.26 Million ≈ $59.60 Million |
+86.67% |
| 2011-12-31 | CN¥218.18 Million ≈ $31.93 Million |
+20.23% |
| 2010-12-31 | CN¥181.47 Million ≈ $26.56 Million |
-34.96% |
| 2009-12-31 | CN¥279.00 Million ≈ $40.83 Million |
-26.32% |
| 2008-12-31 | CN¥378.65 Million ≈ $55.41 Million |
+8.32% |
| 2007-12-31 | CN¥349.58 Million ≈ $51.15 Million |
+70.96% |
| 2006-12-31 | CN¥204.48 Million ≈ $29.92 Million |
-- |
About Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more